Genmab(GMAB) - 2023 Q2 - Earnings Call Transcript

Company Participants expansions? I know the second-line Phase 3 trial, I believe, is fully enrolled now. And you also started the firstline DLBCL trial recently. Just curious sort of how we should think about the pace of possible label expansions into larger markets. And then a follow-up. Your competitor, Roche, is marketing sort of this fixed duration treatment aggressively for their CD20 bispecific antibodies. Just curious if that is something that is under consideration for EPKINLY as well or if you're s ...